Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with obesity was associated with a one-third ...

Researchers found that the study cohort had a significantly lower risk for suicidal ideation or attempts during 12 months of follow-up.

Recent studies have shown that pharmacologic weight loss with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and ...

A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is ...

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and ...

Obesity treatment should start at a young age, he said, because if you have overweight at ages 3-6 years, the likelihood of ...

Researchers find that Semaglutide improves cognitive function and reduces amyloid and tau pathology in Alzheimer's disease ...

Researchers reveal the importance of personalized communication and side effect management in improving outcomes for patients ...

GlobalData’s report assesses the drugs in the Glucagon Like Peptide 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Patients aged 10 to 17 years who are prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are more likely to have ...